Ardelyx begins two clinical trials of RDX7675 to treat hyperkalemia

US-based clinical-stage company Ardelyx has begun a Phase III clinical trial and another onset-of-action clinical trial of RDX7675 to treat hyperkalemia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news